What con­tro­ver­sy? Eli Lil­ly plots Alzheimer's BLA fil­ing lat­er this year as FDA taps more an­ti-amy­loid drugs as break­throughs

The FDA is keep­ing the good news com­ing for Alzheimer’s drug de­vel­op­ers. And Eli Lil­ly is tak­ing them up on it.

Amid con­tin­ued con­tro­ver­sy around whether Bio­gen’s new flag­ship drug, Aduhelm, should have been ap­proved at all — and swelling, heat­ed de­bates sur­round­ing its $56,000 price tag — the agency had no is­sue hand­ing them and their Japan­ese part­ner Ei­sai a break­through ther­a­py des­ig­na­tion for a sec­ond an­ti-amy­loid be­ta an­ti­body, lecanemab, late Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.